The Attractiveness of Investing In Cidara Therapeutics Inc. (CDTX) is Growing


Cidara Therapeutics Inc.’s recently made public that its CHIEF SCIENTIFIC OFFICER Tari Leslie acquired Company’s shares for reported $9700.0 on Aug 14. In the deal valued at $0.97 per share,10,000 shares were bought. As a result of this transaction, Tari Leslie now holds 294,179 shares worth roughly $ 0.23 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Stein Jeffrey bought 50,000 shares, generating $47,885 in total proceeds. Upon buying the shares at $0.96, the President & CEO now owns 331,602 shares.

Before that, Stein Jeffrey bought 50,000 shares. Cidara Therapeutics Inc. shares valued at $51,855 were divested by the President & CEO at a price of $1.04 per share. As a result of the transaction, Stein Jeffrey now holds 281,602 shares, worth roughly $0.22 million.

PT values the company’s stock at a premium of 86.83 to its Friday closing price.

Price Performance Review of CDTX

On Friday, Cidara Therapeutics Inc. [NASDAQ:CDTX] saw its stock jump 0.75% to $0.79. On the same session, the stock had its day’s lowest price of $0.7811, but rose to a high of $0.811. Over the last five days, the stock has gained 1.94%. Cidara Therapeutics Inc. shares have risen nearly 4.46% since the year began. Nevertheless, the stocks have risen 13.55% over the past one year. While a 52-week high of $2.10 was reached on 03/22/23, a 52-week low of $0.46 was recorded on 01/04/23. SMA at 50 days reached $0.9893, while 200 days put it at $1.1103. A total of 0.14 million shares were traded, compared to the trading of 0.31 million shares in the previous session.

Levels Of Support And Resistance For CDTX Stock

The 24-hour chart illustrates a support level at 0.7771, which if violated will result in even more drops to 0.7641. On the upside, there is a resistance level at 0.8070. A further resistance level may holdings at 0.8239. The Relative Strength Index (RSI) on the 14-day chart is 35.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0140, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.88%. Stochastics %K at 26.09% indicates the stock is a holding.

How much short interest is there in Cidara Therapeutics Inc.?

A steep rise in short interest was recorded in Cidara Therapeutics Inc. stocks on Aug 14, 2023, dropping by -0.21 million shares to a total of 1.42 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 1.63 million shares. There was a decline of -14.79%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.60% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.45.

Cidara Therapeutics Inc. [CDTX] – Who Are The Largest Shareholders?

In filings from BVF Partners LP, it is revealed that the company now owns 6,861,127 shares, or roughly 7.62% of the outstanding CDTX shares. Additionally, Nantahala Capital Management LLC decreased -16.23% of its stake after which the total value it holdings stand at $3,942,089. At present, Renaissance Technologies LLC is holding 1,549,573 shares valued at $1.54 million. Apo Asset Management GmbH owned 1,445,926 shares of the company at the time of its most recent 13F filing, worth $1.44 million.

According to FactSet, Cidara Therapeutics Inc.’s share price will average $4.67 in the next year, based on opinions of analysts polled by the firm. This is up nearly 541.03 percent from its previous closing price of $0.78. Analysts expect Cidara Therapeutics Inc. stock to reach the higher price of $6.00, while the lowest price estimate is $3.00. However, 3 analysts have rated CDTX stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here